natgillin/translations-raw huggingface dataset:
When comparing rates of transplant rejection or rates of graft loss between CellCept patients taking PPIs vs. CellCept patients not taking PPIs, no significant differences were seen. 
Pri primerjavi deležev zavrnitve presadka ali deležev izgube presadka med bolniki, ki so jemali zdravilo CellCept in zaviralce protonske črpalke ter bolniki, ki so jemali zdravilo CellCept in niso jemali zaviralcev protonske črpalke, niso opazili značilnih razlik.
Keep solutions at 15 - 30° C. 
Raztopine shranjujte pri temperaturi med 15 °C in 30 °C.
In a single dose study (6 subjects/group), mean plasma MPA AUC observed in subjects with severe chronic renal impairment (glomerular filtration rate < 25 mL/min/1.73 m2) were 28 - 75% higher relative to the means observed in normal healthy subjects or subjects with lesser degrees of renal impairment. 
V študiji enkratnega odmerjanja (6 oseb/skupino) je bil pri bolnikih s hudo kronično ledvično okvaro (glomerulna filtracija < 25 ml/min/1,73 m2) srednji AUC mikofenolne kisline v plazmi za 28 do 75 % večji kot pri bolnikih z blažjimi stopnjami ledvične okvare ali pri zdravih prostovoljcih.
Blood and lymphatic disorders 
Bolezni krvi in limfatičnega sistema
The made-up medicine can be used for 2 months. 
• Rok uporabnosti pripravljenega zdravila je 2 meseca.
The highest dose tested in the animal carcinogenicity studies resulted in approximately 2 - 3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2 g/day. 
Najvišji preizkušani odmerek v živalskih študijah karcinogenosti je povzročil približno 2- do 3-krat večjo sistemsko izpostavljenost (AUC ali Cmax) kot pri bolnikih z ledvičnim presadkom, ki so prejemali priporočeni klinični odmerek
Any unused product or waste material should be disposed of in accordance with local requirements 
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi
During your entire treatment with CellCept 
• ves čas zdravljenja z zdravilom CellCept,
Therapeutic drug monitoring of MPA may be appropriate when switching combination therapy (e.g. from ciclosporin to tacrolimus or vice versa) or to ensure adequate immunosuppression in patients with high immunological risk (e.g. risk of rejection, treatment with antibiotics, addition or removal of an interacting medication). 
Pri zamenjavi kombiniranega zdravljenja (npr. z zdravljenja s ciklosporinom na zdravljenje s takrolimusom ali obratno) ali za zagotovitev ustrezne imunosupresije pri bolnikih z visokim imunološkim tveganjem (npr. tveganjem zavrnitve, zdravljenjem z antibiotiki, dodanim ali ukinjenim zdravilom z medsebojnim delovanjem) je primerno spremljanje terapevtskih koncentracij mikofenolne kisline.
Preparation of Infusion Solution (6 mg/mL) 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Priprava infuzijske raztopine (6 mg/ml)
CellCept contains mycophenolate mofetil. 
Zdravilo CellCept vsebuje mofetilmikofenolat.
Reconstituted solution and infusion solution: If the infusion solution is not prepared immediately prior to administration, the commencement of administration of the infusion solution should be within 3 hours from reconstitution and dilution of the medicinal product. 
Prašek za koncentrat za raztopino za infundiranje: 3 leta Pripravljena raztopina in raztopina za infundiranje: če raztopine za infundiranje ne pripravite takoj pred dajanjem, mora biti začetek dajanja infuzije v 3 urah po rekonstituciji in razredčitvi zdravila.
Patients with a body surface area of 1.25 to 1.5 m2 may be prescribed CellCept capsules at a dose of 750 mg twice daily (1.5 g daily dose). 
Bolnikom s telesno površino med 1,25 in 1,5 m2 predpišemo kapsule CellCept v odmerku 750 mg dvakrat na dan (dnevni odmerek 1,5 g).
Before you start taking CellCept 
• preden boste začeli jemati zdravilo CellCept,
Of these, 991 were included in the three renal studies, 277 were included in one hepatic study, and 289 were included in one cardiac study. 
Od teh je bilo 991 bolnikov vključenih v tri študije preprečevanja zavrnitve ledvičnega presadka, 277 v študijo preprečevanja zavrnitve jetrnega presadka in 289 v študijo preprečevanja zavrnitve srčnega presadka.
Congenital malformations have been observed post-marketing in children of patients exposed to CellCept in combination with other immunosuppressants, see section 4.6. 
Po prihodu zdravila na trg so pri otrocih bolnic, ki so bile izpostavljene zdravilu CellCept v kombinaciji z drugimi imunosupresivi, poročali o kongenitalnih malformacijah; glejte poglavje 4.6.
MPA AUC values obtained following administration of 1 g BID intravenous CellCept to renal transplant patients in the early post-transplant phase are comparable to those observed following 1 g BID oral CellCept. 
AUC vrednosti za mikofenolno kislino, ki so jih pri bolnikih z ledvičnim presadkom opazili pri intravenskem jemanju 1 g zdravila CellCept dvakrat na dan v zgodnjem obdobju po presaditvi, so primerljive z vrednostmi, ki so jih opazili pri jemanju 1 g zdravila CellCept peroralno.
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with CellCept. 
Pri dajanju antacidov, kot so magnezijevi in aluminijevi hidroksidi, in zaviralcev protonske črpalke, vključno z lanzoprazolom in pantroprazolom, skupaj z zdravilom CellCept, so opazili zmanjšano izpostavljenost mikofenolni kislini.
Neoplasms benign, malignant and unspecified (including cysts and polyps) Benign neoplasm of skin 
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi) benigna neoplazma kože limfom limfoproliferativna motnja neoplazma kožni rak
Then, tightly close the bottle with child safety bottle cap. 
Nato steklenico tesno zaprite z za otroke varno zaporko.
If you stop taking CellCept 
Če prenehate jemati zdravilo CellCept
Organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are involved in MPA's disposition; OATP isoforms, MRP2 and breast cancer resistance protein (BCRP) are transporters associated with the glucuronides' biliary excretion. 
Na razporeditev mikofenolne kisline vplivajo organski anionski prenašalni polipeptidi (OATP - Organic anion-transporting polypeptides) in protein za multiplo odpornost na zdravila 2 (MRP2 - Multidrug resistance-associated protein 2).
These effects occurred at systemic exposure levels that are equivalent to or less than the clinical exposure at the recommended dose of 2 g/day. 
Učinki so se pojavili pri sistemski izpostavljenosti, ki je bila enaka ali manjša kot klinična izpostavljenost pri priporočenem odmerjanju 2 g na dan.
• Do not use after the expiry date stated on the carton and bottle label (EXP). 
• Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki steklenice (Uporabno do).
Further dilute the content of the two reconstituted vials (approx. 2 x 15 mL) into 140 mL of glucose intravenous infusion 5%. 
Po rekonstituciji vsebino dveh vial razredčite (približno 2 x 15 ml) v 140 ml intravenske infuzije 5-% glukoze.
Powder for concentrate for solution for infusion. 
prašek za koncentrat za raztopino za infundiranje
Mean plasma MPAG AUC0-12h was 2 - 3-fold higher than in post-transplant patients without delayed graft function. 
Srednja AUC0-12 ur mikofenolglukuronida pa je bila 2- do 3-krat večja kot pri bolnikih brez zapoznelega delovanja ledvičnega presadka.
The contents of CellCept 500 mg powder for concentrate for solution for infusion vials must be reconstituted with 14 mL of glucose intravenous infusion 5% each. 
Vsebino vial z zdravilom CellCept 500 mg prašek za koncentrat za raztopino za infundiranje je treba raztopiti s 14 ml intravenske infuzije 5-% glukoze.
Advice that patients should not donate blood during therapy or for at least 6 weeks following discontinuation of mycophenolate. 
• Nasvet, naj bolniki in bolnice ne darujejo krvi med zdravljenjem in še najmanj 6 tednov po zaključku zdravljenja z mofetilmikofenolatom.
Abnormalities of the ear (e.g. abnormally formed or absent external ear), external auditory canal artesia (middle ear); 
• nenormalna ušesa (npr. nenormalna oblika ali manjkajoče zunanje uho), atrezija zunanjega sluhovoda (srednjega ušesa),
• The shelf-life of the reconstituted suspension is two months. 
• Rok uporabnosti pripravljene suspenzije je 2 meseca.
Do not break or crush them. 
• Tablet ne smete lomiti ali drobiti.
Then shake the closed bottle well for about 1 minute. 
• Nato zaprto steklenico temeljito stresajte približno 1 minuto.
• CellCept capsules are oblong shaped with one end blue and the other end brown. 
• CellCept kapsule so ovalne oblike, en del kapsule je modre, drugi del pa rjave barve.
CellCept capsules pregelatinised maize starch croscarmellose sodium polyvidone (K-90) magnesium stearate 
CellCept kapsule: predgeliran koruzni škrob premrežen natrijev karmelozat povidon (K90) magnezijev stearat
CellCept 500 mg powder for concentrate for solution for infusion solution should not be mixed or administered concurrently via the same catheter with other intravenous medicinal products or infusion admixtures. 
Zdravila CellCept 500 mg prašek za koncentrat za raztopino za infundiranje ne smemo mešati z drugimi infuzijskimi raztopinami ali ga dajati sočasno z istim katetrom z drugimi intravenskimi učinkovinami ali zmesmi infuzij.
Powder for oral suspension and reconstituted suspension: Do not store above 30 °C. 
Prašek za peroralno suspenzijo in pripravljena suspenzija: shranjujte pri temperaturi do 30 °C.
The most common gastrointestinal disorders, however, were diarrhea, nausea and vomiting. 
Najpogostejše bolezni prebavil so bile driska, navzea in bruhanje.
CellCept has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation. 
Pri bolnikih, ki so prejemali zdravilo CellCept, so opazili povišano incidenco neželenih dogodkov v prebavilih, vključno z redkimi primeri razjed v prebavnem traktu, krvavitvami in perforacijami črevesa.
Take care not to let the made-up medicine get onto your skin. 
Bodite previdni, da pripravljeno zdravilo ne pride v stik s kožo.
Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, CellCept capsules should not be opened or crushed to avoid inhalation or direct contact with skin or mucous membranes of the powder contained in CellCept capsules. 
Ker ima mofetilmikofenolat dokazane teratogene učinke pri podganah in kuncih, kapsul CellCept ne smemo odpreti ali drobiti, da se izognemo vdihavanju ali neposrednemu stiku praška v CellCept kapsulah s kožo ali sluznico.
• CellCept treatment should not be initiated in women of childbearing potential without providing a pregnancy test result to rule out unintended use in pregnancy (see section 4.6). 
• Zdravljenja z zdravilom Cellcept ne smemo uvesti pri bolnicah v rodni dobi, ki ne zagotovijo izvida testa nosečnosti, da izključimo nenamerno uporabo zdravila med nosečnostjo (glejte poglavje 4.6).
CellCept 1 g/5 ml powder for oral suspension is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. 
Zdravilo CellCept 1 g/5 ml prašek za peroralno suspenzijo je indicirano skupaj s ciklosporinom in kortikosteroidi za preprečevanje akutnih zavrnitvenih reakcij pri bolnikih z alogenim ledvičnim, srčnim ali jetrnim presadkom.
• CellCept should not be given to women of childbearing potential who are not using highly effective contraception (see section 4.6). 
• Zdravila CellCept ne smemo uporabljati pri bolnicah v rodni dobi, ki ne uporabljajo zelo učinkovitih kontracepcijskih metod (glejte poglavje 4.6).
The first dose is given within 24 hours of the transplant operation. 
Odrasli • Prvi odmerek prejmete v 24 urah po presaditvenem posegu.
CellCept tablets should only be prescribed to patients with a body surface area greater than 1.5 m2, at a dose of 1 g twice daily (2 g daily dose). 
Tablete CellCept lahko predpišemo samo bolnikom, katerih telesna površina je večja od 1,5 m2, v odmerku 1 g dvakrat na dan (dnevni odmerek 2 g).
CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. 
Zdravilo CellCept je indicirano skupaj s ciklosporinom in kortikosteroidi za preprečevanje akutnih zavrnitvenih reakcij pri bolnikih z alogenim ledvičnim, srčnim ali jetrnim presadkom.
• The first dose of oral CellCept will be given to you at least 4 days after the transplant operation and when you are able to swallow oral medicines. 
• Prvi peroralni odmerek zdravila CellCept boste prejeli vsaj 4 dni po presaditvenem posegu in takoj, ko boste lahko jemali zdravila peroralno.
The highest dose tested in the animal carcinogenicity studies resulted in approximately 2 - 3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2 g/day and 1.3 - 2 times the systemic exposure (AUC or Cmax) observed in cardiac transplant patients at the recommended clinical dose of 3 g/day. 
Najvišji preizkušani odmerek v živalskih študijah karcinogenosti je povzročil približno 2- do 3-krat večjo sistemsko izpostavljenost (AUC ali Cmax) kot pri bolnikih z ledvičnim presadkom, ki so prejemali priporočeni klinični odmerek 2 g na dan, in 1,3- do 2-krat večjo sistemsko izpostavljenost (AUC ali Cmax) kot pri bolnikih s srčnim presadkom, ki so prejemali priporočeni klinični odmerek 3 g na dan.
The most common opportunistic infections in patients receiving CellCept (2 g or 3 g daily) with other immunosuppressants in controlled clinical trials in renal and hepatic transplant patients followed for at least 1 year were candida mucocutaneous, CMV viraemia/syndrome and Herpes simplex. 
Najpogostejše oportunistične okužbe pri bolnikih z ledvičnim ali jetrnim presadkom, ki so v nadzorovanih kliničnih preskušanjih prejemali zdravilo CellCept (2 g ali 3 g na dan) z drugimi imunosupresivi vsaj eno leto, so bile okužbe z glivicami (Candida mucocutaneus), sindrom CMV/viremija in okužbe z virusom herpesa simpleksa.
Do not take CellCept if you are breast-feeding. 
Dojenje Ne jemljite zdravila CellCept, če dojite.
You need to use the dispenser and bottle adapter supplied with the medicine to measure the dose. 
Za pripravo ustreznega odmerka potrebujete peroralni razdelilnik in nastavek za steklenico, ki ju dobite skupaj z zdravilom.
There have been reports of hypogammaglobulinaemia in association with recurrent infections in patients receiving CellCept in combination with other immunosuppressants. 
Poročali so o primerih hipogamaglobulinemije v povezavi s ponavljajočimi se okužbami pri bolnikih, ki so prejemali zdravilo CellCept v kombinaciji z drugimi imunosupresivi.
Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, avoid inhalation or direct contact with skin or mucous membranes of the dry powder as well as direct contact of the reconstituted suspension with the skin. 
Ker ima mofetilmikofenolat dokazane teratogene učinke pri podganah in kuncih, se je treba izogibati vdihavanju ali neposrednemu stiku praška s kožo ali sluznico kot tudi neposrednemu stiku rekonstituirane raztopine s kožo.
CellCept 250 mg capsules: 
CellCept 250 mg kapsule:
The systemic exposure at these levels is approximately equivalent to or less than 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day (see section 4.6). 
Sistemska izpostavljenost pri tem odmerku je bila približno enaka ali manj kot 0,5-krat tolikšna kot klinična izpostavljenost pri priporočenem kliničnem odmerku 2 g na dan (glejte poglavje 4.6).
• CellCept should not be used during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection (see section 4.6). 
• Zdravila Cellcept ne smemo uporabljati med nosečnostjo, razen če ni na voljo primernega alternativnega zdravljenja za preprečitev zavrnitve presadka (glejte poglavje 4.6).
If any of the above apply to you (or you are not sure), talk to your doctor or nurse straight away starting treatment with CellCept. 
Če kar koli izmed naštetega velja za vas (ali ste negotovi), se nemudoma pogovorite z zdravnikom ali medicinsko sestro, preden se začnete zdraviti z zdravilom CellCept.
The most common opportunistic infections in patients receiving CellCept (2 g or 3 g daily) with other immunosuppressants in controlled clinical trials in renal, cardiac and hepatic transplant patients followed for at least 1 year were candida mucocutaneous, CMV viraemia/syndrome and Herpes simplex. 
Najpogostejše oportunistične okužbe pri bolnikih z ledvičnim, srčnim ali jetrnim presadkom, ki so v nadzorovanih kliničnih preskušanjih prejemali zdravilo CellCept (2 g ali 3 g na dan) z drugimi imunosupresivi vsaj eno leto, so bile okužbe z glivicami (Candida mucocutaneus), sindrom CMV/viremija in okužbe z virusom herpesa simpleksa.
Shake bottle well before use 
Za peroralno uporabo po pripravi Pred uporabo steklenico dobro pretresite
Metabolism and nutrition disorders Acidosis 
Presnovne in prehranske motnje acidoza
The other ingredients are: polysorbate 80, citric acid, hydrochloric acid, sodium chloride. 
• Pomožne snovi so: polisorbat 80, citronska kislina, klorovodikova kislina, natrijev klorid.
Musculoskeletal and connective tissue disorders Arthralgia 
Bolezni mišično-skeletnega sistema in vezivnega tkiva artralgija
Cardiac disorders Tachycardia 
Srčne bolezni tahikardija
Write the date of expiration of the reconstituted suspension on the bottle label. 
Na nalepko steklenice napišite datum uporabnosti pripravljene suspenzije.
What CellCept contains 
Kaj vsebuje zdravilo CellCept
Paediatric population No data are available for treatment of first or refractory rejection in pediatric transplant patients. 
Pediatrični bolniki Za otroke s presadkom ni na voljo podatkov o zdravljenju prve ali ponovne zavrnitve.
METHOD OF ADMINISTRATION Oral use 
Način uporabe peroralna uporaba
Paediatric population No data are available for paediatric cardiac transplant patients. 
Pediatrični bolniki Za otroke s srčnim presadkom podatkov ni.
The first dose is given within 5 days of the transplant operation. 
• Prvi odmerek prejmete v 5 dneh po presaditvenem posegu.
CellCept 500 mg film-coated tablets 
CellCept 500 mg filmsko obložene tablete
If you have ever had a problem with your digestive system such as a stomach ulcer If you have a rare problem with your metabolism called “phenylketonuria” which runs in families 
• če imate redko dedno motnjo metabolizma, imenovano »fenilketonurija«,
Respiratory, thoracic and mediastinal disorders Bronchiectasis 
Bolezni dihal, prsnega koša in mediastinalnega prostora bronhiektazija kašelj
Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when CellCept was concomitantly administered with sevelamer without any clinical consequences (i.e. graft rejection). 
Pri sočasnem dajanju zdravila CellCept in sevelamerja so opazili zmanjšanje Cmax mikofenolne kisline za 30 % in AUC0-12h mikofenolne kisline za 25 %, kliničnih posledic (zavrnitve presadka) pa ni bilo.
CellCept 500 mg powder for concentrate for solution for infusion is available in packs containing 4 vials. 
Zdravilo CellCept 500 mg prašek za koncentrat za raztopino za infundiranje je na voljo v pakiranju po 4 viale.
Paediatric population aged 2 to 18 years The recommended dose of CellCept 1 g/5 ml powder for oral suspension is 600 mg/m2 administered twice daily (up to a maximum of 2 g/10 mL oral suspension daily). 
Priporočeni odmerek zdravila CellCept 1 g/5 ml prašek za peroralno suspenzijo je 600 mg/m2, dvakrat na dan (do največ 2 g/10 ml peroralne suspenzije na dan).
In hepatic transplant patients, administration of 1 g BID intravenous CellCept followed by 1.5 g BID oral CellCept resulted in MPA AUC values similar to those found in renal transplant patients administered 1 g CellCept BID. 
Pri bolnikih z jetrnim presadkom so se po 1 g intravenskih odmerkih zdravila CellCept dvakrat na dan, ki so jim sledili 1,5 g peroralni odmerki zdravila CellCept dvakrat na dan, pojavile vrednosti AUC mikofenolne kisline podobne vrednostim, ki so jih našli pri bolnikih z ledvičnim presadkom, ki so jemali 1 g zdravila CellCept dvakrat na dan.
Caution should be used during concomitant administration because of the potential to reduce efficacy of CellCept. 
Pri sočasni uporabi holestiramina in zdravila CellCept je potrebna previdnost, saj je lahko učinkovitost zdravila CellCept zmanjšana.
diarrhea, constipation, feeling sick (nausea), indigestion, loss of appetite, flatulence. 
• driska, zaprtje, slabost (navzea), dispepsija, izguba teka, napenjanje.
An increase of MPA AUC0-∞ by 35% was observed with concomitant administration of isavuconazole. 
Pri sočasni uporabi izavukonazola so opazili povečanje AUC0-∞ mikofenolne kisline za 35 %.
The systemic exposure at this dose represents 2 - 3 times the clinical exposure at the recommended clinical dose of 2 g/day. 
Sistemska izpostavljenost pri tem odmerku predstavlja 2- do 3-kratno klinično izpostavljenost pri priporočenem kliničnem odmerku 2 g na dan.
acne, cold sores, skin growth, shingles, hair loss, rash, itching. 
• akne, herpes simpleks, pasasti izpuščaj, rast kože, izguba las, izpuščaj, srbenje.
Capsule shells gelatin indigo carmine (E132) yellow iron oxide (E172) red iron oxide (E172) titanium dioxide (E171) black iron oxide (E172) potassium hydroxide shellac. 
Ovojnica kapsule: želatina indigotin (E132) rumeni železov oksid (E172) rdeči železov oksid (E172) titanov dioksid (E171) črni železov oksid (E172) kalijev hidroksid šelak
5 mL of the reconstituted suspension contains 1 g of mycophenolate mofetil. 
5 ml pripravljene suspenzije vsebuje 1 g mofetilmikofenolata.
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8). 
Bolniki, ki prejemajo kombinacije imunosupresivnih zdravil, vključno z zdravilom CellCept, so izpostavljeni povečanemu tveganju nastanka limfomov in drugih malignih sprememb, zlasti kožnih (glejte poglavje 4.8).
NAME OF THE MARKETING AUTHORISATION HOLDER Roche Registration GmbH. 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Roche Registration GmbH
If you take more CellCept than you should, talk to a doctor or go to a hospital straight away. 
Če ste vzeli večji odmerek zdravila CellCept, kot bi smeli Če ste zaužili več zdravila CellCept, kot bi smeli, takoj obvestite zdravnika ali pojdite v bolnišnico.
CellCept 500 mg powder for concentrate for solution for infusion is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal or hepatic transplants. 
Zdravilo CellCept 500 mg prašek za koncentrat za raztopino za infundiranje je indicirano skupaj s ciklosporinom in kortikosteroidi za preprečevanje akutnih zavrnitvenih reakcij pri bolnikih z alogenim ledvičnim ali jetrnim presadkom.
How to take CellCept 
Kako jemati zdravilo CellCept
The patient information pack should contain: · The Package Leaflet · Guide for patients 
Gradivo za bolnike mora vsebovati:
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4). 
Bolniki, ki prejemajo imunosupresivna zdravila, obsegajoč kombinacije zdravil, vključno z zdravilom CellCept, imajo zvečano tveganje nastanka limfomov in drugih malignih sprememb, zlasti kožnih (glejte poglavje 4.4).
A reduction in the AUC of MPA of approximately 40% is associated with the co-administration of cholestyramine (4 g TID), indicating that there is a significant amount of enterohepatic recirculation. 
Holestiramin v odmerku 4 g 3-krat na dan zmanjša AUC mikofenolne kisline za približno 40 %, kar potrjuje veliko stopnjo ponovnega enterohepatičnega obtoka.